Home monitoring of blood tests for cancer patients
Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.
This study is testing if cancer patients can do their blood tests at home during chemotherapy to make things easier and improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 265 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Pomeranian Medical University Szczecin Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 5 sites (Næstved, Region Sjælland and 4 other locations) |
| Trial ID | NCT06809101 on ClinicalTrials.gov |
What this trial studies
This study aims to implement remote home monitoring of complete blood counts for cancer patients undergoing chemotherapy. By allowing patients to conduct blood tests at home, the study seeks to reduce unnecessary travel and associated costs, while improving patient involvement in their treatment. The research will evaluate the feasibility of this approach across multiple sites in the South Baltic region, focusing on the implementation process and potential changes in patient care pathways. The study will also assess the technology used for home monitoring and gather insights for future investigations.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 or older, diagnosed with cancer, and currently receiving chemotherapy.
Not a fit: Patients who are unable to provide informed consent or have conditions that prevent them from performing blood tests at home will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance patient convenience, reduce healthcare costs, and improve treatment adherence for cancer patients.
How similar studies have performed: While the concept of home monitoring is gaining traction, this specific implementation approach is novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * legally competent patients * aged 18 or older * diagnosed with cancer (ICD-10: C00\* - C97\*) * enrolled at the Department of Oncology/Hematology for outpatients * participants who are willing and able to give informed consent for participation in the study * participants should receive chemotherapy in Daily Chemotherapy Unit and be within 4 weeks of chemotherapy initiation, and the expected duration of chemotherapy should be at least 12 weeks from inclusion Exclusion Criteria: * inability to give informed consent due to mental capacity or language barrier * patient unable or unlikely to be able to perform fine manipulation required to use lancet or cartridge to obtain capillary blood sample and result * known bleeding disorder * bad circulation preventing the patient from getting enough blood drops to perform the test
Where this trial is running
Næstved, Region Sjælland and 4 other locations
- Department of Oncology, Zealand University Hospital — Næstved, Region Sjælland, Denmark (Recruiting)
- Clinic and Polyclinic for Internal Medicine C, Hematology and Oncology, Palliative Care Unit, University Medical Center — Greifswald, Mecklenburg-Vorpommern, Germany (Recruiting)
- Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University Medical Center — Rostock, Mecklenburg-Vorpommern, Germany (Recruiting)
- Department of Oncology and Radiotherapy, University Clinical Center of Gdańsk, — Gdansk, Pomeranian Voivodeship, Poland (Recruiting)
- Department of Hematology and Transplantology — Szczecin, West Pomeranian Voivodeship, Poland (Recruiting)
Study contacts
- Principal investigator: Bogusław Machaliński, MD, PhD, Prof — Department of Hematology and Transplantology, Pomeranian Medical University in Szczecin
- Study coordinator: Bartłomiej Baumert, MD, PhD, DSc
- Email: bartlomiej.baumert@pum.edu.pl
- Phone: +48 91 4250428
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.